GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma

Naik, Meenatai; Rao, Vishal; Fonseca, Daphne; Murthy, Sudha; Giridhar, Ashwin; Sharma, Rakesh; Raju, Kalyani; Rao, T. Subramanyeshwar; Challa, Sundaram

doi:10.1007/s13193-019-01026-0

Cited by 8 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In urothelial cell line models, the loss of GATA3 expression promoted tumor cell migration and invasion via upregulation of oncogenes 28 , 29 . Several clinical studies of GATA3 in bladder cancer have been conducted 30 – 32 . Loss of GATA3 expression was associated with high-grade cancer 32 , and patients with GATA3-negative bladder cancer had poorer survival outcomes in most studies 30 , 31 , 33 .…”

Section: Discussionmentioning

confidence: 99%

“…Several clinical studies of GATA3 in bladder cancer have been conducted 30 – 32 . Loss of GATA3 expression was associated with high-grade cancer 32 , and patients with GATA3-negative bladder cancer had poorer survival outcomes in most studies 30 , 31 , 33 . Taken together, those reports and our data demonstrate that GATA3 is a promising biomarker of MIBC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer

Bejrananda

Kanjanapradit

Saetang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Molecular subtyping of muscle-invasive bladder cancer (MIBC) predicts disease progression and treatment response. However, standard subtyping based on transcriptomic analysis is relatively expensive. This study tried to use immunohistochemistry (IHC) to subtype MIBC based on GATA3, CK20, CK5/6, and CK14 protein expression. The IHC-based subtypes in MIBC subtypes were classified as luminal (GATA3+ CK5/6−, 38.6%), basal (GATA3−CK5/6+, 12.9%), mixed (GATA3+ CK5/6+, 37.9%), and double-negative (GATA3−CK5/6−, 10.6%) in 132 MIBC patients. All individual markers and clinicopathological parameters were analyzed against treatment outcomes after radical cystectomy. The mean patient age was 65.6 years, and the male to female ratio was 6.8:1. Positive IHC expression of GATA3, CK20, CK5/6, and CK14 were 80.3%, 50.8%, 42.4%, and 28.0%, respectively. Only GATA3 and CK5/6 were significantly associated with survival outcome (p values = 0.004 and 0.02). The mixed subtype was significantly better in 5-year OS at 42.8%, whereas the double-negative subtype had the worst prognosis (5-year OS 7.14%). The double-negative subtype had a hazard ratio of 3.29 (95% CI 1.71–6.32). Subtyping using GATA3 and CK5/6 was applicable in MIBCs, and patients with the double-negative subtype were at the highest risk and may require more intensive therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer

Bejrananda

Kanjanapradit

Saetang

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…GATA3 immunoreactivity has been shown to be inversely related to grade, stage, PNI, LVI, the presence of nodal metastases, and an overall poor clinical outcome [ 69 , 116 , 117 , 137 ], both as a direct consequence of down-regulation to loss of GATA3, resulting in neoplastic transformation, migration, and invasion of urothelial-derived tumor cells through up-regulation of oncogenes [ 138 , 139 ], and because of the association between GATA3 down-regulation and up-regulation of epithelial-mesenchymal transition (EMT) molecules, vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP-2 and MMP-9) [ 140 ], the latter being consistently involved in cancer cell migration/invasion, angiogenesis, tumor progression, and metastasis [ 141 ].…”

Section: Combining Immunohistochemical Markers To Subtype Bladder Cancermentioning

confidence: 99%

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression

Sanguedolce

Zanelli

Palicelli

et al. 2022

IJMS

View full text Add to dashboard Cite

Bladder cancer (BC) is a heterogeneous disease with highly variable clinical and pathological features, and resulting in different outcomes. Such heterogeneity ensues from distinct pathogenetic mechanisms and may consistently affect treatment responses in single patients. Thus, over the last few years, several groups have developed molecular classification schemes for BC, mainly based on their mRNA expression profiles. A “consensus” classification has recently been proposed to combine the published systems, agreeing on a six-cluster scheme with distinct prognostic and predictive features. In order to implement molecular subtyping as a risk-stratification tool in routine practice, immunohistochemistry (IHC) has been explored as a readily accessible, relatively inexpensive, standardized surrogate method, achieving promising results in different clinical settings. The first part of this review deals with the steps resulting in the development of a molecular subtyping of BC, its prognostic and predictive implications, and the main features of immunohistochemical markers used as surrogates to stratify BC into pre-defined molecular clusters.

show abstract

“…Immunohistochemistry is not routinely utilized in the diagnosis of low grade papillary urothelial carcinomas. GATA-3 is positive in 97.5% of papillary urothelial neoplasms (24). These lesions can show positive staining in p63, high molecular weight cytokeratin, CK5/6 in the basal layer, and CK7 (25)(26)(27)(28).…”

Section: Non-invasive Low Grade Papillary Urothelial Carcinomamentioning

confidence: 99%

Papillary Urothelial Neoplasms: Clinical, Histologic, and Prognostic Features

Yan¹,

Downes²

2022

Urologic Cancers

View full text Add to dashboard Cite

Primary bladder neoplasms can be divided into two broad categories: flat and papillary lesions. In this chapter, we provide a review of non-invasive papillary urothelial neoplasms of the bladder: urothelial papilloma, inverted urothelial papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), non-invasive low grade papillary urothelial carcinoma, and noninvasive high grade papillary urothelial carcinoma. The following is discussed for each entity: clinical features, etiology, microscopic description, ancillary tests, molecular alterations, and prognostic factors.

show abstract

GATA-3 Expression in all Grades and Different Variants of Primary and Metastatic Urothelial Carcinoma

Cited by 8 publications

References 19 publications

Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer

Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer

Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression

Papillary Urothelial Neoplasms: Clinical, Histologic, and Prognostic Features

Contact Info

Product

Resources

About